Associate Principal Scientist (Associate Director)

About the role

Job Title: Associate Principal Scientist Location: Waltham, MA     The Rare Cancer Unit is a dedicated group within AstraZeneca Oncology R&D focused on discovering and advancing  transformative therapies for patients with rare and underserved cancers —including  neuro-oncology, and other rare malignancies of high unmet needs, where standard-of-care options are limited or nonexistent. The Unit works across modalities including  small molecules, biologics, bioconjugates, targeted protein degraders (PROTACs), gene therapy (AAV/lentivirus), RNA/mRNA therapeutics, and cancer vaccines, and partners closely with translational medicine, clinical development, and external academic collaborators to accelerate first-in-class programs into the clinic.     Position Summary   The Associate Principal Scientist /Associate Director will provide  scientific leadership and hands-on experimental expertise  to rare cancer discovery programs, with a primary focus on  neuro-oncology indications such as glioblastoma  and pediatric brain tumors. The successful candidate will design and execute complex biology experiments across advanced in vitro and orthotopic in vivo models, interpret data to guide program direction, and serve as a key scientific voice across cross-functional teams spanning oncology, immuno-oncology, viral vector engineering, and targeted protein degradation.     Key Responsibilities   Lead and contribute to discovery programs  aimed at identifying novel therapeutic strategies for rare CNS cancers, including  glioblastoma and pediatric brain tumors, encompassing target validation, mechanism-of-action (MOA) studies, and translational research.   Design and execute complex in vitro and in vivo experiments, including  2D/3D glioma models, patient-derived and cell line–derived xenografts, syngeneic mouse models, orthotopic intracranial implantation, and in vivo bioluminescence imaging.   Engineer tumor models  via  lentiviral transduction, AAV delivery, CRISPR/Cas9 editing, and si /shRNA knockdown  to overexpress or ablate targets of interest.   Advance targeted protein degradation strategies (PROTACs)  for oncoprotein degradation in brain and other rare tumors, building on established programs in BRD4 and related targets.   Evaluate novel immunotherapy approaches, targeting TAA and beyond and immune cell engagers, in relevant preclinical models.   Assess the impact of standard of the care (chemo/ radiation, TTF, and combination therapies )  on target expression, tumor behavior, and tumor microenvironment dynamics specific to neurooncology.   Analyze and interpret experimental data  to evaluate therapeutic hypotheses, assess efficacy, potency, and safety signals, and inform go/no-go program decisions.   Serve as scientific liaison across functions, including Neuroscience, Immuno-Oncology, Translational Medicine, and Clinical Development, to advance integrated therapeutic strategies for rare CNS cancers.   Present scientific findings  to internal leadership, governance committees, and external partners; contribute to publications, patents, and regulatory documents.   Provide scientific mentorship  to junior scientists, associates, and postdoctoral fellows, and ensure technical rigor across the team.   Contribute to portfolio strategy  by shaping experimental roadmaps, identifying novel targets, and evaluating external opportunities including academic collaborations and in-licensing.     Minimum Qualifications   PhD  in Cell Biology, Cancer Biology, Molecular Biology, or a closely related discipline.   5+ years  of postdoctoral and/or industry experience in  oncology drug discovery or translational research, with demonstrated productivity in  neuro-oncology.   Demonstrated expertise in  glioblastoma and pediatric brain tumor (DIPG) biology, advanced cellular models, and  orthotopic intracranial in vivo models.   Hands-on experience with  AAV and lentivirus production, CRISPR/Cas9 engineering, and viral vector–based therapeutics.   Experience with  targeted protein degradation (PROTACs)  and small-molecule mechanism-of-action characterization.   Strong publication record in peer-reviewed journals in oncology, neuro-oncology, and molecular biology.   Proven ability to work in  cross-functional, matrixed environments.   Preferred Qualifications   Dual training or experience spanning  cancer biology, neuro-oncology, and immuno-oncology.   Experience with  immune cell engagers, immune checkpoint modulation (, and combination immunotherapy strategies.   Experience with  high-throughput drug screening  (96/384-well formats) and DNA damage response biology.   Familiarity with  rare disease drug development, regulatory pathways, and orphan drug designation.   Experience co-directing or managing  core facilities  and leading laboratory operations.   Track record of  peer review and scientific service  in oncology and molecular biology journals.   Experience mentoring scientists and leading small project teams.   Multi-lingual communication skills to support global collaborations.     Key Competencies   Scientific leadership and independent judgment   Cross-disciplinary communication across oncology, neuroscience, and immunology   Data-driven decision-making   Collaboration and stakeholder management   Innovation and strategic thinking   Operational excellence in laboratory and vector core management       The annual base pay (or hourly rate of compensation) for this position ranges from $131,201 to $196,802. Our positions offer eligibility for various incentives—an opportunity to receive short-term incentive bonuses, equity-based awards for salaried roles and commissions for sales roles. Benefits offered include qualified retirement programs, paid time off (i.e., vacation, holiday, and leaves), as well as health, dental, and vision coverage in accordance with the terms of the applicable plans. As AstraZeneca continues to put patients at the forefront of our mission, we are excited for our move to Kendall Square/Cambridge in 2026. Find out more information here: Kendall Square Press Release AstraZeneca is an equal opportunity employer that is committed to diversity and inclusion and providing a workplace that is free from discrimination. AstraZeneca is committed to accommodating persons with disabilities. Such accommodation is available on request in respect of all aspects of the recruitment, assessment and selection process and may be requested by emailing . #LI-Hybrid Date Posted 27-Aug-2026 Closing Date 03-Sept-2026 Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.